Lawmakers question Vytorin cancer risk data
WASHINGTON (Reuters) - Two top Democratic lawmakers on Thursday questioned recent claims by Merck & Co Inc and Schering Plough Corp that incidents of cancer in patients taking their cholesterol drug Vytorin were a fluke.
The lawmakers, Rep. John Dingell and Rep. Bart Stupak, both from Michigan, are seeking 10 years of related company records after a study last month found Vytorin patients had a higher rate of cancer than those taking a placebo.
(Reporting by Susan Heavey; editing by John Wallace)
© Thomson Reuters 2009 All rights reserved
Finding the profit prescription
Pharmaceutical companies are striking mega deals, diversifying and cutting costs but Wall Street skepticism persists in many corners of the healthcare industry. Full Coverage
Obama vows "justice" for shooter